Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 93

1.

Molecule of the Month. TAK-875.

[No authors listed]

Drug News Perspect. 2010 Dec;23(10):667. doi: 10.1358/dnp.2010.23.10.1560199. No abstract available.

PMID:
21180652
[PubMed - indexed for MEDLINE]
2.

Optimization of (2,3-dihydro-1-benzofuran-3-yl)acetic acids: discovery of a non-free fatty acid-like, highly bioavailable G protein-coupled receptor 40/free fatty acid receptor 1 agonist as a glucose-dependent insulinotropic agent.

Negoro N, Sasaki S, Mikami S, Ito M, Tsujihata Y, Ito R, Suzuki M, Takeuchi K, Suzuki N, Miyazaki J, Santou T, Odani T, Kanzaki N, Funami M, Morohashi A, Nonaka M, Matsunaga S, Yasuma T, Momose Y.

J Med Chem. 2012 Apr 26;55(8):3960-74. doi: 10.1021/jm300170m. Epub 2012 Apr 18.

PMID:
22490067
[PubMed - indexed for MEDLINE]
3.

A novel antidiabetic drug, fasiglifam/TAK-875, acts as an ago-allosteric modulator of FFAR1.

Yabuki C, Komatsu H, Tsujihata Y, Maeda R, Ito R, Matsuda-Nagasumi K, Sakuma K, Miyawaki K, Kikuchi N, Takeuchi K, Habata Y, Mori M.

PLoS One. 2013 Oct 10;8(10):e76280. doi: 10.1371/journal.pone.0076280. eCollection 2013.

PMID:
24130766
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Activation of GPR40 as a therapeutic target for the treatment of type 2 diabetes.

Burant CF.

Diabetes Care. 2013 Aug;36 Suppl 2:S175-9. doi: 10.2337/dcS13-2037. Review.

PMID:
23882043
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

GPR40: a therapeutic target for mediating insulin secretion (review).

Feng XT, Leng J, Xie Z, Li SL, Zhao W, Tang QL.

Int J Mol Med. 2012 Dec;30(6):1261-6. doi: 10.3892/ijmm.2012.1142. Epub 2012 Sep 26. Review.

PMID:
23023155
[PubMed - indexed for MEDLINE]
6.

Deal watch: Metabolex and Sanofi-Aventis partner on GPCR agonists for type 2 diabetes.

[No authors listed]

Nat Rev Drug Discov. 2010 Sep;9(9):670. doi: 10.1038/nrd3255. No abstract available.

PMID:
20811370
[PubMed - indexed for MEDLINE]
7.

High-resolution structure of the human GPR40 receptor bound to allosteric agonist TAK-875.

Srivastava A, Yano J, Hirozane Y, Kefala G, Gruswitz F, Snell G, Lane W, Ivetac A, Aertgeerts K, Nguyen J, Jennings A, Okada K.

Nature. 2014 Sep 4;513(7516):124-7. doi: 10.1038/nature13494. Epub 2014 Jul 20.

PMID:
25043059
[PubMed - indexed for MEDLINE]
8.

Fasiglifam as a new potential treatment option for patients with type 2 diabetes.

Kaku K.

Expert Opin Pharmacother. 2013 Dec;14(18):2591-600. doi: 10.1517/14656566.2013.851668. Epub 2013 Nov 6. Review.

PMID:
24195772
[PubMed - indexed for MEDLINE]
9.

Discovery of novel orally bioavailable GPR40 agonists.

Lu H, Fei H, Yang F, Zheng S, Hu Q, Zhang L, Yuan J, Feng J, Sun P, Dong Q.

Bioorg Med Chem Lett. 2013 May 15;23(10):2920-4. doi: 10.1016/j.bmcl.2013.03.060. Epub 2013 Mar 26.

PMID:
23582779
[PubMed - indexed for MEDLINE]
10.

GPR119 agonists for the potential treatment of type 2 diabetes and related metabolic disorders.

Shah U, Kowalski TJ.

Vitam Horm. 2010;84:415-48. doi: 10.1016/B978-0-12-381517-0.00016-3. Review.

PMID:
21094910
[PubMed - indexed for MEDLINE]
11.

[Discovery and development of a selective GPR40/FFAR1 agonist, fasiglifam, for treatment of type 2 diabetes mellitus].

Tsujihata Y.

Nihon Yakurigaku Zasshi. 2014 Aug;144(2):59-63. Japanese. No abstract available.

PMID:
25109517
[PubMed - indexed for MEDLINE]
12.

Discovery and optimization of a novel series of GPR142 agonists for the treatment of type 2 diabetes mellitus.

Lizarzaburu M, Turcotte S, Du X, Duquette J, Fu A, Houze J, Li L, Liu J, Murakoshi M, Oda K, Okuyama R, Nara F, Reagan J, Yu M, Medina JC.

Bioorg Med Chem Lett. 2012 Sep 15;22(18):5942-7. doi: 10.1016/j.bmcl.2012.07.063. Epub 2012 Jul 23.

PMID:
22884988
[PubMed - indexed for MEDLINE]
13.

GPR119 agonists: a promising new approach for the treatment of type 2 diabetes and related metabolic disorders.

Shah U.

Curr Opin Drug Discov Devel. 2009 Jul;12(4):519-32. Review.

PMID:
19562648
[PubMed - indexed for MEDLINE]
14.

Diabetes treatment.

Bloomgarden ZT.

Diabetes Care. 2009 Mar;32(3):e25-30. doi: 10.2337/dc09-zb03. No abstract available.

PMID:
19246581
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Progress in the discovery and development of small-molecule modulators of G-protein-coupled receptor 40 (GPR40/FFA1/FFAR1): an emerging target for type 2 diabetes.

Bharate SB, Nemmani KV, Vishwakarma RA.

Expert Opin Ther Pat. 2009 Feb;19(2):237-64. doi: 10.1517/13543770802665717. Review.

PMID:
19441920
[PubMed - indexed for MEDLINE]
16.

Molecule of the month. XOMA-052.

[No authors listed]

Drug News Perspect. 2009 Oct;22(8):497. No abstract available.

PMID:
20016858
[PubMed - indexed for MEDLINE]
17.

AS1907417, a novel GPR119 agonist, as an insulinotropic and β-cell preservative agent for the treatment of type 2 diabetes.

Yoshida S, Tanaka H, Oshima H, Yamazaki T, Yonetoku Y, Ohishi T, Matsui T, Shibasaki M.

Biochem Biophys Res Commun. 2010 Oct 1;400(4):745-51. doi: 10.1016/j.bbrc.2010.08.141. Epub 2010 Sep 15.

PMID:
20816753
[PubMed - indexed for MEDLINE]
18.

SAR, pharmacokinetics, safety, and efficacy of glucokinase activating 2-(4-sulfonylphenyl)-N-thiazol-2-ylacetamides: discovery of PSN-GK1.

Bertram LS, Black D, Briner PH, Chatfield R, Cooke A, Fyfe MC, Murray PJ, Naud F, Nawano M, Procter MJ, Rakipovski G, Rasamison CM, Reynet C, Schofield KL, Shah VK, Spindler F, Taylor A, Turton R, Williams GM, Wong-Kai-In P, Yasuda K.

J Med Chem. 2008 Jul 24;51(14):4340-5. doi: 10.1021/jm8003202. Epub 2008 Jun 28.

PMID:
18588279
[PubMed - indexed for MEDLINE]
19.

The significance of GPR119 agonists as a future treatment for type 2 diabetes.

Dhayal S, Morgan NG.

Drug News Perspect. 2010 Sep;23(7):418-24. doi: 10.1358/dnp.2010.23.7.1468395. Review.

PMID:
20862393
[PubMed - indexed for MEDLINE]
20.

Inhibition of insulin secretion as a new drug target in the treatment of metabolic disorders.

Hansen JB, Arkhammar PO, Bodvarsdottir TB, Wahl P.

Curr Med Chem. 2004 Jun;11(12):1595-615. Review.

PMID:
15180566
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk